Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

151
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
151
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

169
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
169
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

144
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
144
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

79.9K
Overview
79.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Nature cancer·2026
Same author

A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection.

Kidney360·2026
Same author

Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management.

Nature reviews. Nephrology·2026
Same author

Erratum: Clinically relevant cut-points for changes in the Liver Frailty Index are associated with waitlist mortality in patients with cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

BLIMP1 shapes germinal center B cell clonal diversity by gating chromatin accessibility during light-to-dark zone transition.

Nature immunology·2026
Same author

Subclinical and Borderline Rejection are Associated With Death-Censored Graft Loss After Kidney Transplantation: A Systematic Review and Meta-Analysis.

Clinical transplantation·2026

Related Experiment Video

Updated: Nov 16, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Transitional B cell cytokines predict renal allograft outcomes.

Aravind Cherukuri1,2, Alan D Salama3, Rajil Mehta1,2

  • 1Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Science Translational Medicine
|February 25, 2021
PubMed
Summary

A novel biomarker, the ratio of interleukin-10 (IL-10) to tumor necrosis factor-α (TNFα) from transitional-1 B cells (T1B), accurately predicts renal allograft rejection and outcomes. This finding supports preemptive therapy to improve long-term graft survival.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.4K
Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry
09:04

Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry

Published on: April 19, 2017

13.7K

Related Experiment Videos

Last Updated: Nov 16, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.4K
Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry
09:04

Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry

Published on: April 19, 2017

13.7K

Area of Science:

  • Immunology
  • Transplantation immunology
  • Biomarker discovery

Background:

  • Early detection of renal allograft rejection is crucial for timely intervention and improved patient outcomes.
  • Current biomarkers lack the sensitivity to predict both early and late rejection events.
  • Identifying reliable immunological markers is essential for guiding preemptive therapeutic strategies.

Purpose of the Study:

  • To evaluate the ratio of interleukin-10 (IL-10) to tumor necrosis factor-α (TNFα) produced by transitional-1 B cells (T1B) as a predictive biomarker for renal allograft rejection.
  • To assess the biomarker's ability to predict clinical and subclinical rejection, subsequent graft outcomes, and the potential for preemptive therapy.

Main Methods:

  • Prospective analysis of the T1B IL-10/TNFα ratio in training, internal validation, and external validation cohorts of kidney transplant recipients.
  • Correlation of the biomarker ratio with the incidence of early and late clinical and subclinical allograft rejection within the first year post-transplant.
  • Assessment of the biomarker's association with renal function and long-term graft survival (5 years).
  • In vitro studies investigating the effect of anti-TNFα treatment on T1B cell function.

Main Results:

  • The T1B IL-10/TNFα ratio at 3 months post-transplant significantly predicted both early and late renal allograft rejection in all validation sets.
  • High-risk patients identified by the biomarker had a substantially higher incidence of rejection and poorer 5-year graft survival.
  • The biomarker demonstrated a lead time of approximately 8 months for predicting late rejection events.
  • In vitro anti-TNFα treatment modulated the T1B IL-10/TNFα ratio, restored regulatory function, and inhibited plasmablast differentiation.

Conclusions:

  • The T1B IL-10/TNFα ratio is a validated and robust predictive biomarker for renal allograft rejection and long-term outcomes.
  • This biomarker facilitates the identification of high-risk patients who may benefit from preemptive therapeutic interventions.
  • Targeting TNF blockade presents a promising therapeutic strategy for improving renal allograft survival based on this biomarker.